Abstracts tagged "physical function"

Abstract Number: 612 • 2019 ACR/ARP Annual Meeting
Objective Ankylosing Spondylitis Physical Performance Index (ASPI) Is Highly Reliable and Feasible in Chilean Patients
Rianne van Bentum¹, Sebastian Ibáñez Vodnizza ², Francisca Valenzuela Aldridge ², Maria Paz Poblete ³, Salima van weely ⁴, Marieke ter Wee ¹, Omar Valenzuela ⁵ and Irene van der Horst-Bruinsma ¹, ¹Amsterdam Rheumatology and immunology Center, Rheumatology, Amsterdam University Medical Center location VUmc, Amsterdam, Amsterdam, Netherlands, ²Rheumatology dpt., Clínica Alemana - UDD Medicine faculty, Santiago, Chile, ³Rheumatology dpt., Facultad de Medicina Clinica Alemana - UDD, Santiago, Region Metropolitana, Chile, ⁴Orthopedics, Rehabilitation and Physical Therapy dpt., Leiden University Medical Center, Leiden, Netherlands, ⁵Facultad de Medicina Clinica Alemana -UDD, Santiago, Region Metropolitana, Chile
Background/Purpose: In axial spondyloarthritis (axSpA), preservation of physical functioning is an important treatment goal and is usually assessed with the patient-reported BASFI questionnaire. The Ankylosing…
Abstract Number: 1170 • 2019 ACR/ARP Annual Meeting
Cortical Bone Erosion in the 2nd Metacarpal Bone Head: Association with Its Bone Mineral Density by HR-pQCT in Rheumatoid Arthritis Patients
Camille Figueiredo¹, Mariana Perez ¹, Ana Cristina de Medeiros Ribeiro ², Valeria Caparbo ¹ and Rosa Pereira ³, ¹Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Sao Paulo, Brazil, ²Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Sao Paulo, Brazil, ³Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Sao Paulo, Brazil
Background/Purpose: Periarticular trabecular bone loss and local cortical bone erosions are typical features of bone disease in rheumatoid arthritis (RA) 1 . Little, however, is…
Abstract Number: 1314 • 2019 ACR/ARP Annual Meeting
Patient-Specific Reference Values for Objective Physical Function Tests: Cross-Sectional Analysis Using Data from the Osteoarthritis Initiative
Matthew Harkey¹, Lori Lyn Price ², Kieran Reid ³, Grace Lo ⁴, Shao-Hsien Liu ⁵, Kate Lapane ¹, Lucas Dantas ⁶, Timothy McAlindon ⁷ and Jeffrey Driban ⁷, ¹University of Massachusetts Medical School, Worcester, ²Tufts Medical Center, Tufts University, Boston, MA, ³Tufts University, Boston, ⁴Center of Excellence Michael E. DeBakey VAMC, Baylor College of Medicine, Houston, TX, ⁵University of Massachusetts Medical School, Worcester, MA, ⁶Tufts Medical Center, Boston, ⁷Tufts Medical Center, Boston, MA
Background/Purpose: Despite an inter-play between objective physical function measures and various patient characteristics, no large-scale investigations in knee osteoarthritis (KOA) have explored complex interactions or…
Abstract Number: 1352 • 2019 ACR/ARP Annual Meeting
Effects of Upadacitinib on Patient-Reported Outcomes After 24 Weeks in Patients with Active Rheumatoid Arthritis and an Inadequate Response to Conventional Synthetic or Biologic Disease-Modifying Anti-Rheumatic Drugs: Results from SELECT-NEXT and SELECT-BEYOND Phase 3 Studies
Martin Bergman¹, Namita Tundia ², Heidi Camp ², Sebastian Meerwein ³, Casey Schlacher ², Debbie Goldschmidt ⁴, Yan Song ⁵ and Vibeke Strand ⁶, ¹Drexel University College of Medicine, Stockholm, Sweden, ²AbbVie Inc., North Chicago, IL, ³AbbVie GmbH Co. KG, Ludwigshafen, Germany, Wiesbaden, Germany, ⁴Analysis Group, Inc., New York, NY, ⁵Analysis Group, Inc., Boston, MA, ⁶Division of Immunology/Rheumatology, Stanford University, Stanford, CA
Background/Purpose: Treatment with upadacitinib (UPA), a selective Janus kinase-1 (JAK-1) inhibitor, resulted in significant and clinically meaningful improvements in patient-reported outcomes (PROs) at Week 12…
Abstract Number: 1375 • 2019 ACR/ARP Annual Meeting
Patient-Reported Outcomes of Upadacitinib versus Adalimumab Use in Patients with Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate: 26-Week Analysis of a Phase 3 Study
Roy Fleischmann¹, Martin Bergman ², Namita Tundia ³, In-Ho Song ⁴, Jessica Suboticki ⁴, Yan Song ⁵ and Vibeke Strand ⁶, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Drexel University College of Medicine, Stockholm, Sweden, ³AbbVie Inc., North Chicago, IL, ⁴AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ⁵Analysis Group, Inc., Boston, MA, ⁶Division of Immunology/Rheumatology, Stanford University, Stanford, CA
Background/Purpose: In patients with active rheumatoid arthritis (RA), 12-week treatment with upadacitinib (UPA) while on background MTX therapy resulted in significant and clinically meaningful improvements…
Abstract Number: 1376 • 2019 ACR/ARP Annual Meeting
Impact of 24- or 26-Week Upadacitinib Monotherapy on Patient-Reported Outcomes in Patients with Moderately to Severely Active Rheumatoid Arthritis and No Prior Use of or an Inadequate Response to Methotrexate: Results from Two Phase 3 Trials
Vibeke Strand¹, Namita Tundia ², Alan Friedman ³, Heidi Camp ², Jessica Suboticki ⁴, Debbie Goldschmidt ⁵, Catherine Fernan ⁵ and Martin Bergman ⁶, ¹Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ²AbbVie Inc., North Chicago, IL, ³AbbVie Inc., North Chicago, ⁴AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ⁵Analysis Group, Inc., New York, NY, ⁶Drexel University College of Medicine, Stockholm, Sweden
Background/Purpose: Treatment with upadacitinib (UPA) monotherapy, a selective Janus kinase-1 (JAK-1) inhibitor, resulted in significant and clinically meaningful improvements in patient-reported outcomes (PROs) at Week…
Abstract Number: 2089 • 2019 ACR/ARP Annual Meeting
Restricting Activity to Evade Knee Symptoms Is Associated with Worse Physical Function and Radiographic Osteoarthritis
Louise Thoma¹, Jason Jakiela ², Hiral Master ¹, Dana Voinier ², Meredith Christiansen ² and Daniel White ¹, ¹University of Delaware, Newark, DE, ²University of Delaware, Newark
Background/Purpose: Activity restriction (i.e. limiting or avoiding normal activity) is a common strategy to reduce, and sometimes eliminate, knee symptoms. Knee symptoms, such as pain,…
Abstract Number: 2160 • 2019 ACR/ARP Annual Meeting
Myopenia Is an Independent Risk Factor for Rotator Cuff Tear and Shoulder Dysfunction in Elderly People : Data from NAMGARAM Cohort
Yun-Hong Cheon¹, Young Sun Suh ², Mingyo Kim ¹, Ki-Soo Park ³ and Sang-Il Lee ¹, ¹Divison of Rheumatology, Gyeongsang National University Hospital, Jin-Ju, Republic of Korea, ²Divison of Rheumatology, Gyeongsang National University Hospital, Changwon, Changwon, Republic of Korea, ³Preventive Medicine, Gyeongsang National University Hospital, Jin-Ju, Republic of Korea
Background/Purpose: Myopenia refers to decline in muscle mass with age, causing significant impairment in the ability to carry out normal daily functions. Rotator cuff tear…
Abstract Number: 555 • 2018 ACR/ARHP Annual Meeting
Three Year Outcomes of Patients with Elderly-Onset Rheumatoid Arthritis Treated with a Therapeutic Strategy Targeting Low Disease Activity, and Impact of Adverse Events on Physical Function
Takahiko Sugihara¹, Tatsuro Ishizaki², Hiroyuki Baba³, Takumi Matsumoto³, Shoko Iga¹, Takeshi Kusuda¹, Marina Tsuchida¹, Mari Kamiya³, Yoji Komiya³, Fumio Hirano⁴, Tadashi Hosoya³, Nobuyuki Miyasaka³ and Masayoshi Harigai⁵, ¹Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ²Human Care Research Team, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan, ³Department of Medicine and Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan, ⁴Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Department of Rheumatology, Tokyo, Japan, ⁵Tokyo Women's Medical University, Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo, Japan
Background/Purpose: The aim of this study was to evaluate three year outcomes of patients with elderly-onset RA (EORA) who were treated with a therapeutic strategy…
Abstract Number: 1407 • 2018 ACR/ARHP Annual Meeting
Differences in the Measurement Properties of the Patient-Reported Outcomes Measurement Information System Physical Function Short-Form 10a Among Racial/Ethnic Minorities with Rheumatoid Arthritis
Zara Izadi¹, Patricia Katz², Gabriela Schmajuk³, Julie Gandrup⁴, Jing Li⁵, Milena Gianfrancesco⁶ and Jinoos Yazdany⁷, ¹Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, ²University of California San Francisco, San Francisco, CA, ³Medicine/Rheumatology, University of California - San Francisco, San Francisco, CA, ⁴Rheumatology, Odense University Hospital, Odense, Denmark, ⁵Medicine, UC San Francisco, San Francisco, CA, ⁶Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁷University of California, San Francisco, San Francisco, CA
Background/Purpose: Most studies evaluating patient-reported outcomes such as the PROMIS Physical Function Short Form 10a (PF10a) in rheumatoid arthritis (RA) have been performed in white…
Abstract Number: 1676 • 2018 ACR/ARHP Annual Meeting
Health Related Quality of Life over Time in a Multi-Ethnic Cohort of Patients with Systemic Lupus Erythematosus and Correlation with Disease Activity and Organ Damage
Muhammad Mehmood Riaz^1,2, Liang SHEN³, Lay Kheng Teoh⁴, Rangi Kandane-Rathnayake⁵ and Aisha Lateef⁶, ¹Department of Medicine, National University Hospital, Singapore, Singapore, ²Department of Medicine, Aga Khan University, karachi, Pakistan, ³Biostatistics Unit, National University Health System, Singapore, Singapore, ⁴National University Hospital, Division of Rheumatology, University Medicine Cluster, Singapore, Singapore, ⁵School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ⁶Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic disease affecting the physical, social, and psychological well-being of patients. Health related quality of life (HRQoL) measures…
Abstract Number: 1953 • 2018 ACR/ARHP Annual Meeting
Randomized Trial on Exercise at Late-Stage after Total Knee Replacement
Sara R. Piva¹, Michael Schneider¹, Charity Moore-Patterson¹, M. Beatriz Catelani¹, Alexandra Gil¹, Brian Klatt², Anthony DiGioia³, Gustavo J. Almeida¹, Samannaaz S. Khoja⁴, Gwendolin Sowa⁵ and James Irrgang¹, ¹Physical Therapy, University of Pittsburgh, Pittsburgh, PA, ²Orthopaedic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, ³University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴Department of Physical Therapy, University of Pittsburgh, Pittsburgh, PA, ⁵Physical Medicine and Rehabilitation, University of Pittsburgh Medical Center, Pittsburgh, PA
Background/Purpose: Total knee replacement (TKR) improves pain and quality of life; however, the functional limitations that existed for years before surgery tend to persist after…
Abstract Number: 2150 • 2018 ACR/ARHP Annual Meeting
Association of Poverty Income Ratio with Physical Functioning in a Cohort of Patients with Systemic Lupus Erythematosus
Courtney Hoge¹, C. Barrett Bowling², S. Sam Lim³, Cristina Drenkard⁴ and Laura Plantinga⁵, ¹Department of Epidemiology, Emory University, Atlanta, GA, ²Durham Veterans Affairs Medical Center, Durham, NC, ³Emory University School of Medicine, Atlanta, GA, ⁴Medicine/Rheumatology, Emory University, Atlanta, GA, ⁵Department of Medicine, Emory University School of Medicine, Atlanta, GA
Background/Purpose: Lower socioeconomic status (SES) has been shown to be associated with poor physical functioning in systemic lupus erythematosus (SLE) patients; however, previous studies have…
Abstract Number: 2470 • 2018 ACR/ARHP Annual Meeting
The Impact of Frailty on Changes in Physical Function Among Adults with Rheumatoid Arthritis
James Andrews¹, Laura Trupin², Catherine Hough¹, Edward H. Yelin³ and Patricia Katz², ¹Medicine, University of Washington, Seattle, WA, ²University of California San Francisco, San Francisco, CA, ³Medicine/Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Frailty is a state of excess vulnerability to stressors and is associated with increased risk of poor health outcomes including physical disability. Frailty and…
Abstract Number: 630 • 2017 ACR/ARHP Annual Meeting
Effects of Intravenous Golimumab, an Anti-Tnfα Monoclonal Antibody, on Mental and Physical Functioning and Health-Related Quality of Life in Active Psoriatic Arthritis: 24-Week Results of a Phase 3 Trial
M. Elaine Husni¹, Arthur Kavanaugh², Eric K. H. Chan³, Nan Li⁴, Steven Peterson⁴, Elizabeth C. Hsia⁵, Lilianne Kim⁴, Kim Hung Lo⁴ and Diane D. Harrison⁴, ¹Rheumatology, Cleveland Clinic, Cleveland, OH, ²Medicine, University of California, San Diego, La Jolla, CA, ³Janssen Global Services, LLC, Raritan, NJ, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA
Background/Purpose: To evaluate physical and mental health functioning, health state, and health-related quality of life (HRQoL) in patients with active psoriatic arthritis (PsA) treated with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].